Research
Hormonal
Tirzepatide (5-15 mg weekly) produces superior weight loss (10.7-20.9%) compared to placebo in adults with obesity (BMI ≥30 or ≥27 with comorbidities) via dual GIP/GLP-1 receptor agonism.
Tirzepatide is a once-weekly injection that significantly reduces body weight (up to 20%+) in obese adults. It works by mimicking gut hormones to suppress appetite and slow digestion. Start with the lowest dose and increase gradually to minimize stomach upset. Combine with a 500-calorie daily deficit and 150 minutes of weekly exercise for best results.
StrongSupportsHIGH confidence
Tirzepatide demonstrated significant weight reduction across studies: SURMOUNT-1 (15.0%, 19.5%, 20.9% weight loss for 5, 10, 15 mg doses respectively)... Adverse effects were mostly gastrointestinal, with nausea, diarrhea, and vomiting being the most common, leading to a discontinuation rate of 4.6%.
Why this rating
Based on multiple phase 2 and 3 randomized, placebo-controlled trials.
Source
TIRZEPATIDE IN OBESITY MANAGEMENT: EFFICACY AND SAFETY - INSIGHTS FROM RECENT CLINICAL TRIALS
Jakub Cecot et al. · Archiv Euromedica · 2024
narrative_review · n=5385
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →